

Psilocybin-Associated Transient Multidomain Functional Recovery in Advanced Alzheimer's Disease: Lessons from a Landmark Case Report and the Wider Evidence Landscape

Tyler Kjorvestad, MD

The popular press has highlighted a striking case report published in *Frontiers in Neuroscience* describing transient but multidomain functional improvement in an octogenarian woman with advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration ^[1]. The New York Post coverage brought the findings to a wide audience, describing an 80-year-old patient with a 10-year history of Alzheimer's (including five years of marked hypofunction, monosyllabic speech, chronic urinary incontinence, executive dysfunction, dysphagia, dependent mobility, and flat affect) who, after receiving 5 g of psilocybin-containing mushrooms (Enigma strain), experienced spontaneous autobiographical speech approximately 19 hours post-administration, followed by progressive improvements in continence, ambulation, autonomous dressing, emotional responsiveness, eye contact, social interaction, contextual memory recollection, and engagement in conversation ^[1]. A second 3 g session one month later further enhanced verbal expressivity, humor, and gait agility, with continence persisting ^[1].

As a clinician whose work has consistently examined the therapeutic potential and limitations of psychedelic compounds across psychiatric and emerging neurologic indications, I approach this report with the same measured, evidence-based framework that has characterized my prior analyses. The case is both compelling and humbling. It does not demonstrate disease reversal, as the authors explicitly note, but it does raise the hypothesis that residual functional capacity in late-stage neurodegeneration may persist and become transiently accessible under specific

neuromodulatory conditions ^[1]. This editorial integrates the NY Post coverage and full case details with the comprehensive evidence review provided, examines mechanistic plausibility, safety, and ethical aspects, and delivers practical recommendations for the field.

Case Report

The patient's baseline state reflected profound, longstanding deficits consistent with advanced Alzheimer's disease ^[1]. The intervention was observational and exploratory, with no established dosing framework for dementia. The acute phase included autonomic activation, suspected hyperthermia, profuse sweating, and a prolonged, deep-sleep-like state ^[1]. The subsequent improvements were objective and spanned autonomic, motor, executive, memory, affective, and social domains ^[1]. Particularly notable was the restoration of urinary continence after more than five years of chronic incontinence, a function that relies on integrated interoceptive awareness, executive inhibition, and fronto-insular networks ^[1]. One-month follow-up confirmed sustained continence and a positive subjective experience ("It is pleasant to come here") ^[1].

This single-case observation is consistent with the larger trend seen in my earlier editorials on ketamine in psychotic disorders and psilocybin versus SSRIs: dramatic, sometimes unexpected functional shifts in refractory conditions can occur under psychedelic influence, yet they must be interpreted with extreme caution in the absence of controlled data ^[2, 3]. The authors correctly emphasize that causality cannot be established and spon-

taneous fluctuations cannot be excluded [1]. Nevertheless, the report functions as a powerful signal for hypothesis generation.

Mechanistic Plausibility: Converging Pathways Supported by Preclinical Data

The case gains substantial weight when situated within the extensive mechanistic literature. Classical serotonergic psychedelics act primarily as 5-HT_{2A} receptor agonists, a receptor highly expressed in cortical regions critical for cognition and dysregulated across the Alzheimer's continuum [4, 5]. Beyond acute receptor agonism, these compounds engage downstream signaling cascades, including BDNF/TrkB, mTOR, and sigma-1 receptor (Sig-1R) pathways, which converge on processes impaired in Alzheimer's disease: synaptic plasticity, neuroinflammation, mitochondrial function, and network connectivity [6–9].

Landmark preclinical work has shown that psychedelics promote structural neuroplasticity (“psychoplastogenesis”) through intracellular 5-HT_{2A} receptor activation localized to the Golgi apparatus [10]. A single dose of psilocybin can produce approximately a 10% increase in dendritic spine size and density that persists for a month [11]. LSD and psilocin bind TrkB (the BDNF receptor) with affinities roughly 1,000-fold higher than conventional antidepressants, and plasticity/antidepressant-like effects in preclinical models depend on TrkB but are independent of 5-HT_{2A} for the behavioral component [12]. A systematic review of 20 studies confirmed rapid changes in plasticity-related genes and proteins, with effects outlasting acute drug action [13].

Anti-neuroinflammatory effects have been demonstrated in 29 of 36 preclinical studies measuring cytokines, with suppression of TNF- α and other markers in activated microglia via multiple serotonergic and TrkB pathways [14, 15]. The strongest direct evi-

dence for disease-relevant pathology modification comes from DMT, which, when chronically administered in triple-transgenic AD mice, markedly alleviated cognitive impairment, reduced amyloid- β accumulation, restored sigma-1 receptor levels, and preserved ER-mitochondria contacts and calcium dynamics [16]. Sigma-1 receptor agonism attenuates amyloid toxicity, rescues LTP, improves memory in A β models, and synergizes with donepezil [17–19]. Default mode network modulation and increased global integration provide additional theoretical support for compensating AD-related network dysfunction [20, 21].

Despite the mechanistic promise, human data specific to Alzheimer's remain essentially absent [22]. No completed randomized controlled trials exist. Geriatric representation in the broader psychedelic literature is minimal; of approximately 1,400 patients across 36 trials, only 19 were aged 65 or older, with detailed safety data for just 10 [23]. A phase 1 low-dose LSD study in healthy older adults demonstrated excellent tolerability with no cognitive impairment [24]. The Parkinson's disease open-label psilocybin pilot (n=12) showed sustained improvements in depression, anxiety, and non-motor symptoms [25]. Indirect support comes from psychedelic therapy for end-of-life distress, where reductions in anxiety, depression, and demoralization have been observed [26]. A registered phase 2 trial of psilocybin for depression in early-stage Alzheimer's (NCT04123314) has not yet reported results [27].

Microdosing, often proposed as a safer approach for dementia, lacks supportive controlled evidence and may weaken cognitive control [28–30].

Safety, Ethical, and Practical Challenges in the Dementia Context

Psilocybin-Associated Transient Multidomain Functional Recovery in Advanced Alzheimer's Disease: Lessons from a Landmark Case Report and the Wider Evidence Landscape

Cardiovascular effects are well documented, including increased blood pressure and heart rate across dose ranges [31, 32]. Chronic microdosing raises concerns regarding 5-HT_{2B}-mediated cardiac fibrosis [33]. In patients with dementia, the altered sensorium risks compounding disorientation and precipitating delirium-like states [34]. A systematic review noted serious adverse events in approximately 4% of participants with preexisting neuropsychiatric conditions [35].

Informed consent and decisional capacity present fundamental barriers. Moderate-to-severe dementia typically precludes the understanding required for a consciousness-altering intervention [36, 37]. The psychotherapeutic framework central to psychedelic protocols may be difficult or impossible for many patients to engage [38]. Drug interactions with cholinesterase inhibitors remain unstudied, and serotonin syndrome risk with concurrent serotonergic agents is a pharmacodynamic concern [39].

These realities reinforce the consistent position across my work: medicalization with rigorous supervision, appropriate screening, trained facilitators, and ethical supervision is mandatory [40, 41].

Areas of Future Research

An unresolved tension exists regarding mTOR: psychedelics activate this pathway for plasticity, yet mTOR hyperactivation in Alzheimer's suppresses autophagy and promotes pathology [42, 43]. This paradox, along with uncertainties about stage-specific 5-HT_{2A} receptor dysregulation, optimal dosing, long-term safety in elderly populations with impaired cognition, and whether effects are disease-modifying versus transiently symptomatic, defines the current frontier [44]. Emerging directions include non-hallucinogenic psychoplastogens that retain TrkB-mediated plasticity without acute subjective effects, potentially bypassing consent and

safety barriers [45]. Serotonergic psychedelics as epigenetic modulators represent another nascent but promising angle [46].

Summary and Recommendations

The Lago et al. case report [1] and the broader evidence reviewed here illustrate both the intriguing potential and the considerable translational challenges of applying classical psychedelics to Alzheimer's disease. Preclinical mechanisms are robust and convergent, particularly DMT/Sig-1R effects on amyloid and mitochondria, neuroplasticity promotion, and anti-inflammatory actions. Human data, however, remain limited to one case report, a small safety study in healthy older adults, a Parkinson's pilot, and indirect end-of-life findings.

The most promising near-term application is likely psilocybin for neuropsychiatric symptoms (depression, anxiety, existential distress) in early-stage Alzheimer's, where patients retain capacity for informed consent and psychotherapeutic engagement—a hypothesis currently under investigation. Larger, controlled trials with biomarker confirmation, standardized outcomes, detailed safety monitoring, and capacity protocols are urgently needed. Development of non-hallucinogenic analogs needs to be prioritized. Until robust data accrue, responsible practice demands restraint, multidisciplinary collaboration, and observance of the highest ethical and evidence-based standards.

The field stands at an inflection point. Disciplined investigation may clarify whether these compounds can offer meaningful relief to patients and families confronting one of medicine's most devastating conditions.

AUTHOR INFORMATION

Tyler Kjorvestad, MD.
(tkjorvestad@kumc.edu)

Kjorvestad, T (2026, June). Psilocybin-Associated Transient Multidomain Functional Recovery in Advanced Alzheimer's Disease: Lessons from a Landmark Case Report and the Wider Evidence Landscape. *The Journal of Psychedelic Psychiatry*, 8(2).

REFERENCES:

1. Lago, M., Cerveira, M., & Simonet, J. X. (2026). Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: A case report. *Frontiers in Neuroscience*, 20, 1813281. <https://doi.org/10.3389/fnins.2026.1813281>
2. Kjorvestad, T. (Year). Selective use of ketamine in patients with psychotic disorders. *Journal of Psychedelic Psychiatry*. (Internal reference to author's prior work)
3. Kjorvestad, T. (Year). Psilocybin therapy—A breakthrough alternative to SSRIs for depression. *Journal of Psychedelic Psychiatry*. (Internal reference to author's prior work)
4. Saeger, H. N., & Olson, D. E. (2022). Psychedelic-inspired approaches for treating neurodegenerative disorders. *Journal of Neurochemistry*, 162(1), 109–127. <https://doi.org/10.1111/jnc.15544>
5. Reiff, C. M., Richman, E. E., Nemeroff, C. B., et al. (2020). Psychedelics and psychedelic-assisted psychotherapy. *The American Journal of Psychiatry*, 177(5), 391–410. <https://doi.org/10.1176/appi.ajp.2019.19010035>
6. Hosein, M. M., Reid, M. J., Walser, S., et al. (2025). Considerations and cautions for the integration of psilocybin into routine clinical care. *EClinicalMedicine*, 89, 103517. <https://doi.org/10.1016/j.eclinm.2025.103517>
7. Bradley, E. R., Sakai, K., Fernandes-Osterhold, G., et al. (2025). Psilocybin therapy for mood dysfunction in Parkinson's disease: An open-label pilot trial. *Neuropsychopharmacology*, 50(8), 1200–1209. <https://doi.org/10.1038/s41386-025-02097-0>
8. Bouchet, L., Sager, Z., Yroni, A., et al. (2024). Older adults in psychedelic-assisted therapy trials: A systematic review. *Journal of Psychopharmacology*, 38(1), 33–48. <https://doi.org/10.1177/02698811231215420>
9. Family, N., Maillet, E. L., Williams, L. T. J., et al. (2020). Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. *Psychopharmacology*, 237(3), 841–853. <https://doi.org/10.1007/s00213-019-05417-7>
10. Schipper, S., Nigam, K., Schmid, Y., et al. (2024). Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. *The Cochrane Database of Systematic Reviews*, 9, CD015383. <https://doi.org/10.1002/14651858.CD015383.pub2>
11. Zheng, S., Ma, R., Yang, Y., & Li, G. (2024). Psilocybin for the treatment of Alzheimer's disease. *Frontiers in Neuroscience*, 18, 1420601. <https://doi.org/10.3389/fnins.2024.1420601>
12. Kozłowska, U., Nichols, C., Wiatr, K., & Figiel, M. (2022). From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. *Journal of Neurochemistry*, 162(1), 89–108. <https://doi.org/10.1111/jnc.15509>

13. Winkelman, M. J., Szabo, A., & Frecska, E. (2023). The potential of psychedelics for the treatment of Alzheimer's disease and related dementias. *European Neuropsychopharmacology*, 76, 3–16. <https://doi.org/10.1016/j.euro-neuro.2023.07.003>
14. Garcia-Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. (2022). Psychedelics as novel therapeutics in Alzheimer's disease: Rationale and potential mechanisms. *Current Topics in Behavioral Neurosciences*, 56, 287–317. https://doi.org/10.1007/7854_2021_267
15. Lashgari, N. A., Khalaji, M., Rana, P., et al. (2025). Psychedelics in the treatment of neurologic and psychiatric disorders: Coincidence or a new point of view. *Molecular Neurobiology*. Advance online publication. <https://doi.org/10.1007/s12035-025-05097-9>
16. Cheng, D., Lei, Z. G., Chu, K., et al. (2024). N, N-dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer's disease by restoring neuronal sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk. *Alzheimer's Research & Therapy*, 16(1), 95. <https://doi.org/10.1186/s13195-024-01462-3>
17. An, Y., Qi, Y., Li, Y., et al. (2022). Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer's disease mice. *Neuroscience Letters*, 774, 136528. <https://doi.org/10.1016/j.neulet.2022.136528>
18. Djebari, S., Jiménez-Herrera, R., Iborra-Lázaro, G., Jiménez-Díaz, L., & Navarro-López, J. D. (2025). Social and contextual memory impairments induced by amyloid- β oligomers are rescued by sigma-1 receptor activation. *Biomedicine & Pharmacotherapy*, 184, 117914. <https://doi.org/10.1016/j.bio-pha.2025.117914>
19. Maurice, T. (2016). Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. *Behavioural Brain Research*, 296, 270–278. <https://doi.org/10.1016/j.bbr.2015.09.020>
20. Frecska, E., Kovács, A., & Szabo, A. (2025). The protective effect of DMT against neurodegeneration. *International Review of Neurobiology*, 181, 395–420. <https://doi.org/10.1016/bs.irn.2025.04.010>
21. Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025). Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling. *International Immunopharmacology*, 159, 114940. <https://doi.org/10.1016/j.intimp.2025.114940>
22. Vargas, M. V., Dunlap, L. E., Dong, C., et al. (2023). Psychedelics promote neuroplasticity through the activation of intracellular 5-HT_{2A} receptors. *Science*, 379(6633), 700–706. <https://doi.org/10.1126/science.adf0435>
23. Bouchet, L., Sager, Z., Yroni, A., et al. (2024). Older adults in psychedelic-assisted therapy trials: A systematic review. *Journal of Psychopharmacology*, 38(1), 33–48. <https://doi.org/10.1177/02698811231215420>
24. Family, N., Maillet, E. L., Williams, L. T. J., et al. (2020). Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. *Psychopharmacology*, 237(3), 841–853. <https://doi.org/10.1007/s00213-019-05417-7>

25. Bradley, E. R., Sakai, K., Fernandes-Osterhold, G., et al. (2025). Psilocybin therapy for mood dysfunction in Parkinson's disease: An open-label pilot trial. *Neuropsychopharmacology*, 50(8), 1200–1209.
<https://doi.org/10.1038/s41386-025-02097-0>
26. Schipper, S., Nigam, K., Schmid, Y., et al. (2024). Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. *The Cochrane Database of Systematic Reviews*, 9, CD015383.
<https://doi.org/10.1002/14651858.CD015383.pub2>
27. Zheng, S., Ma, R., Yang, Y., & Li, G. (2024). Psilocybin for the treatment of Alzheimer's disease. *Frontiers in Neuroscience*, 18, 1420601.
<https://doi.org/10.3389/fnins.2024.1420601>
28. Pinhas, N., Eidlman, N., Barnea, A., & Peled-Avron, L. (2025). Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis. *Neuroscience and Biobehavioral Reviews*. Advance online publication. <https://doi.org/10.1016/j.neubio-rev.2025.106493>
29. Prochazkova, L., Marschall, J., Lippelt, D. P., et al. (2025). Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials. *Neuropharmacology*. Advance online publication. <https://doi.org/10.1016/j.neuropharm.2025.110722>
30. Wießner, I., Olivieri, R., Falchi, M., et al. (2022). LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility. *European Neuropsychopharmacology*, 58, 7–19.
<https://doi.org/10.1016/j.euro-neuro.2022.01.114>
31. Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. *JAMA Psychiatry*, 81(12), 1225–1235.
<https://doi.org/10.1001/jamapsychiatry.2024.2546>

